EGEIRO PHARMA
A bankruptcy procedure is open for EGEIRO PHARMA according to publications in the Belgian State Gazette. The 2023 annual accounts show equity of €6.05M and a net result of €-1.57M.
| Equity | €6.05M |
| Net result | €-1.57M |
| Staff (FTE) | 7.5 |
| Better than sector | 85% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Bankruptcy opened
A bankruptcy procedure is already open, a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 80.3% | 25.2% | |
| Net result | €-1.57M | €-3k | |
| Equity | €6.05M | €35k | |
| Staff costs | €770k | €548k | |
| Employees (FTE) | 7.5 | 14.3 |
| Fiscal year | 2023 |
|---|---|
| Deposit | volledig |
| Revenue | €118k |
| EBITDA | €-1.11M |
| Net profit | €-1.57M |
| Cash flow | €-507k |
| Staff costs | €770k |
| Income taxes | €-46k |
| Dividends | - |
| Total assets | €7.53M |
| Equity | €6.05M |
| Debt | €1.48M |
| of which ≤ 1y | €477k |
| of which > 1y | €1.00M |
| Working capital | €1.17M |
| Employees (FTE) | 7.5 |
| 2023 | |
|---|---|
| Current ratio | 3.45 |
| Quick ratio | 3.19 |
| Working capital ratio | 15.5% |
| Solvency | 80.3% |
| Debt / equity | 0.25 |
| Long-term debt ratio | 0.17 |
| Interest coverage | -40.28 |
| Gross margin | 36.7% |
| Net margin | -1332.9% |
| ROA | -20.8% |
| ROE | -26.0% |
| EBITDA margin | -942.9% |
| Days sales outstanding | 56d |
| Days payable outstanding | 644d |
| Inventory turnover | 0.60 |
| Days inventory (DSI) | 604d |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €7.53M |
| Fixed assets | 21/28 | €5.44M |
| Formation expenses | 20 | €452k |
| Intangible fixed assets | 21 | €5.21M |
| Tangible fixed assets | 22/27 | €22k |
| Financial fixed assets | 28 | €201k |
| Current assets | 29/58 | €1.65M |
| Stocks & contracts in progress | 3 | €123k |
| Amounts receivable within one year | 40/41 | €334k |
| Cash & bank | 54/58 | €1.15M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €7.53M |
| Equity | 10/15 | €6.05M |
| Contributions / capital | 10/11 | €10.17M |
| Accumulated profits (losses) | 14 | €-5.84M |
| Amounts payable | 17/49 | €1.48M |
| Amounts payable after one year | 17 | €1.00M |
| Amounts payable within one year | 42/48 | €477k |
| Trade debts payable within one year | 44 | €132k |
| Income statement | ||
| Turnover | 70 | €118k |
| Operating result | 9901 | €-2.18M |
| Financial income | 75 | €594k |
| Financial charges | 65 | €35k |
| Result before taxes | 9903 | €-1.62M |
| Income taxes | 67/77 | €-46k |
| Net result for the period | 9904 | €-1.57M |
| Result to be appropriated | 9905 | €-1.57M |
-
Catherine Suzanne Madeleine BurDirectorState Gazette act 24442799 (12-11-2024)Current12-11-2024 → present
-
Emmanuel Gilbert Hyunh-Kim-BangDirectorState Gazette act 24442799 (12-11-2024)Current12-11-2024 → present
-
Gaëtan TerrasseDaily management delegateState Gazette act 24175571 (13-12-2024)Current12-11-2024 → present
2 events
- 13-12-2024 Appointed· Daily management delegate
- 12-11-2024 Appointed· Director
-
FATAKI BVLegal entityDirectorState Gazette act 24108740 (18-07-2024)Current18-07-2024 → present
-
Mélanie AdoranteRepresentative of the commissionerState Gazette act 23079634 (20-06-2023)Current20-06-2023 → present
-
NESYA GORIS LIFESCIENCES CONSULTING BVLegal entityDirectorState Gazette act 22074510 (23-06-2022)Current22-02-2022 → present
2 events
- 23-06-2022 Appointed· Director
- 22-02-2022 Appointed· Director
-
Vel-Vet AH ConsultingObservateurState Gazette act 22024019 (22-02-2022)Current22-02-2022 → present
-
Innovation Fund SALegal entityDirectorState Gazette act 21069923 (14-06-2021)Current14-06-2021 → present
Historic, not recently confirmed (3)
-
Christian JourquinAdministratorState Gazette act 18091382 (13-06-2018)Not recently confirmedlast confirmed in an act from 2018
-
Mohamed Lotfi Yelles ChaoucheAdministratorState Gazette act 18091382 (13-06-2018)Not recently confirmedlast confirmed in an act from 2018
-
Pierre DetrixheAdministratorState Gazette act 18091382 (13-06-2018)Not recently confirmedlast confirmed in an act from 2018
Former directors (12)
-
Catherine BURDaily management delegateState Gazette act 24165401 (22-11-2024)Former22-11-2024 → 13-12-2024
2 events
- 13-12-2024 Resigned· Daily management delegate
- 22-11-2024 Appointed· Daily management delegate
-
ENRICO BASTIANELLIDirectorState Gazette act 24442799 (12-11-2024)Former13-06-2018 → 13-12-2024
4 events
- 13-12-2024 Resigned· Director
- 12-11-2024 Resigned· Director
- 12-11-2024 Appointed· Director
- 13-06-2018 Appointed· Administrator
-
ENRICO BASTIANELLI SRLLegal entityDirectorState Gazette act 24108740 (18-07-2024)Former18-07-2024 → 22-11-2024
2 events
- 22-11-2024 Resigned· Daily management delegate
- 18-07-2024 Appointed· Director
-
FatakiDirectorState Gazette act 24442799 (12-11-2024)Former- → 12-11-2024
-
Nesya Goris LifeSciences ConsultingDirectorState Gazette act 24442799 (12-11-2024)Former- → 12-11-2024
-
Simon WheelerDirectorState Gazette act 22074510 (23-06-2022)Former22-02-2022 → 12-11-2024
4 events
- 12-11-2024 Resigned· Director
- 23-06-2022 Appointed· Director
- 22-02-2022 Appointed· Director
- 22-02-2022 Appointed· Président du conseil
-
CAPITAL & CROISSANCE SCRLLegal entityDirectorState Gazette act 23149336 (23-11-2023)Former- → 23-11-2023
-
Julie WinandAdministratorState Gazette act 18091382 (13-06-2018)Former13-06-2018 → 23-11-2023
2 events
- 23-11-2023 Resigned· Director
- 13-06-2018 Appointed· Administrator
-
Patrick MortouxRepresentative of the commissionerState Gazette act 23079634 (20-06-2023)Former- → 20-06-2023
-
VEL-VET AH CONSULTING SASDirectorState Gazette act 22074510 (23-06-2022)Former23-06-2022 → 05-01-2023
2 events
- 05-01-2023 Resigned· Director
- 23-06-2022 Appointed· Director
-
EEBIC Ventures SALegal entityDirectorState Gazette act 21069923 (14-06-2021)Former14-06-2021 → 22-02-2022
3 events
- 22-02-2022 Resigned· Director
- 22-02-2022 Resigned· Président du conseil
- 14-06-2021 Appointed· Director
-
André OstachkovDirectorState Gazette act 21125397 (21-10-2021)Former- → 21-10-2021
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Mélanie AdoranteCurrent Commissaire |
- | 10-11-2022 → present |
| SC PwC Réviseurs d'EntreprisesCurrent Commissaire |
- | 23-06-2022 → present |
| Patrick Mortroux Commissaire aux comptes |
- | 13-08-2020 → 10-11-2022 |
| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | PIERRE-EMMANUEL CORNIL RUE DE GOZEE, 137,
6110 MONTIGNY-LE-TILLEUL |
17-03-2025 → present | Belgian State Gazette |
| NACE primary | Vervaardiging van andere anorganische chemische basisproducten(20130) |
| Legal form | Public limited company(014) |
| Incorporation | 22-11-2017 |
| Status | Active |
| Postal code | 6041 |
| First BS signal | 21-03-2025 |
| Latest BS signal | 21-03-2025 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52028B0315/18E000 | Wallonia | 2,954 m² | 1 · 670 m² | 10.0 m · 2 fl. |
| 21307F0170/00S002 | Brussels | 2,186 m² | 1 · 2,167 m² | 17.9 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
20-12-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}17-12-2024 Capital increase of €33,138.20 to €12,254,462.48
- €12.221.324,28 → €12.254.462,48
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 12254462.48,
"delta_eur": 33138.20000000112,
"before_eur": 12221324.28,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}13-12-2024 1 director appointed, 2 resigning
- Gaëtan Terrasse, Dagelijks bestuur
- Enrico Bastianelli, Bestuurder
- Catherine Bur, Dagelijks bestuur
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Enrico Bastianelli",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Catherine Bur",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Ga\u00EBtan Terrasse",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}22-11-2024 1 director appointed, 1 resigning
- Catherine BUR, Dagelijks bestuur
- ENRICO BASTIANELLI SRL, Dagelijks bestuur
Technical details
{
"events": [
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "ENRICO BASTIANELLI SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Catherine BUR",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}12-11-2024 Capital increase of €11,864,406.78 to €12,221,324.28
- €356.917,50 → €12.221.324,28
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 12221324.28,
"delta_eur": 11864406.78,
"before_eur": 356917.5,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}18-09-2024 Capital increase of €15,495.80 to €356,917.50
- €341.421,70 → €356.917,50
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 356917.5,
"delta_eur": 15495.799999999988,
"before_eur": 341421.7,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}06-09-2024 Capital increase of €19,008.10 to €341,421.70
- €322.413,60 → €341.421,70
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 341421.7,
"delta_eur": 19008.100000000035,
"before_eur": 322413.6,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}18-07-2024 2 directors appointed
- FATAKI BV, Bestuurder
- ENRICO BASTIANELLI SRL, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "FATAKI BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "ENRICO BASTIANELLI SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}23-11-2023 2 resigning
- Julie WINAND, Bestuurder
- CAPITAL & CROISSANCE SCRL, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Julie WINAND",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "CAPITAL \u0026 CROISSANCE SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}20-06-2023 1 director appointed, 1 resigning
- Mélanie Adorante, Representative of the commissioner
- Patrick Mortoux, Representative of the commissioner
Technical details
{
"events": [
{
"kind": "director_in",
"role": "representative of the commissioner",
"person": {
"rrn": null,
"name": "M\u00E9lanie Adorante",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representative of the commissioner",
"person": {
"rrn": null,
"name": "Patrick Mortoux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}05-01-2023 VEL-VET AH CONSULTING SAS resigns as director
- VEL-VET AH CONSULTING SAS, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "VEL-VET AH CONSULTING SAS",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}10-11-2022 1 director appointed, 1 resigning
- Mélanie Adorante, Commissaire
- Patrick Mortroux, Commissaire
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "M\u00E9lanie Adorante",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Patrick Mortroux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}23-06-2022 4 directors appointed
- NESYA GORIS LIFESCIENCES CONSULTING BV, Bestuurder
- Simon Wheeler, Bestuurder
- VEL-VET AH CONSULTING SAS, Bestuurder
- SC PwC Réviseurs d'Entreprises, Commissaire
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "NESYA GORIS LIFESCIENCES CONSULTING BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "VEL-VET AH CONSULTING SAS",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "SC PwC R\u00E9viseurs d\u0027Entreprises",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}22-02-2022 4 directors appointed, 2 resigning
- Nesya Goris LifeSciences Consulting BV, Bestuurder
- Simon Wheeler, Bestuurder
- Simon Wheeler, Président du conseil
- Vel-Vet AH Consulting, Observateur
- EEBIC Ventures SA, Bestuurder
- EEBIC Ventures SA, Président du conseil
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Nesya Goris LifeSciences Consulting BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Pr\u00E9sident du Conseil",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Pr\u00E9sident du Conseil",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "observateur",
"person": {
"rrn": null,
"name": "Vel-Vet AH Consulting",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "Innovation Fund SA"
}
}21-10-2021 André Ostachkov resigns as director
- André Ostachkov, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Andr\u00E9 Ostachkov",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}30-09-2021 Registered office moved from Jumet to Charleroi
- Rue d'Edimbourg 11, boite B, 6040 Jumet → 6041 Charleroi, Avenue Jean Mermoz 32/1, Bâtiment BIOTECH 3
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "6041 Charleroi, Avenue Jean Mermoz 32/1, B\u00E2timent BIOTECH 3",
"city": "Charleroi",
"region": "waals_gewest",
"street": "Avenue Jean Mermoz",
"country": "BE",
"postcode": "6041",
"box_number": null,
"street_number": "32/1",
"locality_suffix": null
},
"old_address": {
"raw": "Rue d\u0027Edimbourg 11, boite B, 6040 Jumet",
"city": "Jumet",
"region": "waals_gewest",
"street": "Rue d\u0027Edimbourg",
"country": "BE",
"postcode": "6040",
"box_number": "B",
"street_number": "11",
"locality_suffix": null
},
"effective_date": "2021-09-15",
"evidence_quote": "Les Administrateurs d\u00E9cident de transf\u00E9rer le si\u00E8ge de la Soci\u00E9t\u00E9 \u00E0 6041 Charleroi, Avenue Jean Mermoz 32/1, B\u00E2timent BIOTECH 3, avec effet au 15 septembre 2021.",
"region_changed": false,
"is_statute_change": false,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "retroactive",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "Bjorn Delmoiti\u00E9",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2021-09-30",
"filing_date": "2021-09-13",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "raad_van_bestuur",
"date": "2021-09-13",
"unanimous": true
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": "Harvest Avocats",
"person_name": "Adrien Lanotte",
"org_rep_person_name": "Bjorn Delmoiti\u00E9",
"person_role_at_subject": "avocat"
},
"co_filed_documents": [
"Extrait des r\u00E9solutions \u00E9crites et unanimes des administrateurs",
"Procuration aux avocats"
]
}12-07-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": true
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
},
"legal_form_change": {
"new": "soci\u00E9t\u00E9 anonyme",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}14-06-2021 2 directors appointed
- EEBIC Ventures SA, Bestuurder
- Innovation Fund SA, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Innovation Fund SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}13-08-2020 Patrick Mortroux appointed as commissaire aux comptes
- Patrick Mortroux, Commissaire aux comptes
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "Patrick Mortroux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVEET"
}
}22-06-2020 Capital increase of €114,025 to €248,930
- €134.905 → €248.930
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 248930,
"delta_eur": 114025,
"before_eur": 134905,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}06-11-2018 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "TheraVet",
"old": "BoneVet",
"changed": true
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-06-2018 5 directors appointed
- Enrico Bastianelli, Administrator
- Julie Winand, Administrator
- Mohamed Lotfi Yelles Chaouche, Administrator
- Christian Jourquin, Administrator
- Pierre Detrixhe, Administrator
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Enrico Bastianelli",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Julie Winand",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Mohamed Lotfi Yelles Chaouche",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Christian Jourquin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Pierre Detrixhe",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "BONEVET"
}
}15-01-2018 Capital increase of €44,967 to €107,467
- €62.500 → €107.467
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 107467,
"delta_eur": 44967,
"before_eur": 62500,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "BoneVet"
}
}24-11-2017 Incorporation of a new SA
Technical details
{
"notary": {
"name": "Bertrand NERINCX",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2017-11-24",
"filing_date": "2017-11-22",
"act_kind_objet": "Objet de l\u0027acte:",
"is_private_deed": false
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2017-11-21",
"unanimous": true
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1969-01-18",
"name": "Enrico BASTIANELLI",
"niss": null,
"address": "1640 Rhode-Saint-Gen\u00E8se, Avenue de la Lib\u00E9ration 41",
"nationality": "Belgique",
"place_of_birth": "Ixelles, Belgique"
},
"share_class": null,
"partner_role": null,
"contribution_type": "geld",
"amount_paid_in_eur": 56250.0,
"is_subscriber_only": false,
"n_shares_subscribed": 56250,
"amount_subscribed_eur": 56250.0,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0547.864.809",
"name": "GLOB-CO",
"address": "6041 Charleroi (Gosselies), Rue Adrienne Bolland 8",
"country": "BE",
"legal_form": "BV",
"foreign_register_name": null,
"foreign_register_number": null
},
"kind": "rechtspersoon",
"person": null,
"share_class": null,
"partner_role": null,
"contribution_type": "geld",
"amount_paid_in_eur": 6250.0,
"is_subscriber_only": false,
"n_shares_subscribed": 6250,
"amount_subscribed_eur": 6250.0,
"is_anonymous_silent_partner": false
}
],
"voorwerp": {
"full_text": "La soci\u00E9t\u00E9 a pour objet, tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger, pour compte propre ou pour compte de tiers, toutes activit\u00E9s se rapportant directement ou indirectement \u00E0 la recherche, \u00E0 la conception, \u00E0 la validation, au d\u00E9veloppement, \u00E0 la production, au conditionnement, et \u00E0 la distribution ou commercialisation de compos\u00E9s chimiques ou radiochimiques, de m\u00E9dicaments, de produits biotechnologiques, de dispositifs m\u00E9dicaux, de formulations gal\u00E9niques originales de m\u00E9dicaments, ainsi que de produits sp\u00E9cifiques de recherche m\u00E9dicale, pharmaceutique, cosm\u00E9tique et biotechnologique pour la sant\u00E9 v\u00E9t\u00E9rinaire et pour la sant\u00E9 humaine ou toute mati\u00E8re dans les domaines pr\u00E9cit\u00E9s. La soci\u00E9t\u00E9 peut rendre des services de soutien et conseil dans les domaines pr\u00E9cit\u00E9s \u00E0 des tiers et en particulier, \u00E0 des soci\u00E9t\u00E9s dans lesquelles elle d\u00E9tient une participation directe ou indirecte. Elle aura aussi pour objet tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger la d\u00E9tention et la gestion, directement ou indirectement, de participations dans d\u2019autres soci\u00E9t\u00E9s ayant un objet directement ou indirectement li\u00E9 \u00E0 la recherche, au d\u00E9veloppement, \u00E0 des activit\u00E9s industrielles ou commerciales se focalisant principalement mais non exclusivement sur l\u2019industrie pharmaceutique, biotechnologique ou des dispositifs m\u00E9dicaux. Elle aura plus g\u00E9n\u00E9ralement pour objet toutes les op\u00E9rations commerciales, financi\u00E8res, industrielles, mobili\u00E8res ou immobili\u00E8res se rattachant directement ou indirectement \u00E0 son objet social ou de nature \u00E0 en favoriser le d\u00E9veloppement, en ce compris toutes op\u00E9rations en rapport avec l\u2019exploitation de droits intellectuels quelconques et autres marques, brevets, inventions, droit d\u2019usage, licences. La soci\u00E9t\u00E9 peut r\u00E9aliser son objet, directement ou indirectement, en nom propre ou pour compte de tiers, seule ou en association en effectuant toutes op\u00E9rations de nature \u00E0 favoriser le dit objet ou celui des soci\u00E9t\u00E9s, associations, \u00E9tablissements dans lesquels elle d\u00E9tient une participation. La soci\u00E9t\u00E9 peut \u00E9galement donner caution ou octroyer des s\u00FBret\u00E9s tant pour ses propres engagements que pour les engagements des tiers, entre autres, en donnant ses biens en hypoth\u00E8que ou en gage, y compris en gageant son fonds de commerce. La soci\u00E9t\u00E9 pourra exercer tous mandats relatifs \u00E0 l\u0027administration, \u00E0 la gestion, \u00E0 la direction, au contr\u00F4le et \u00E0 la liquidation de toutes soci\u00E9t\u00E9s ou entreprises. La soci\u00E9t\u00E9 pourra \u00E9galement s\u0027int\u00E9resser de quelque mani\u00E8re que ce soit et notamment par voie de cr\u00E9ation de soci\u00E9t\u00E9s, d\u2019apports et de fusions, de souscriptions ou d\u2019achats de titres, de droits sociaux et de participations dans toutes entreprises dont l\u0027activit\u00E9 ou l\u2019objet serait similaire ou connexe en tout ou en partie \u00E0 celui ci-dessus d\u00E9crit et qui serait susceptible de concourir au d\u00E9veloppement de ses activit\u00E9s, en Belgique comme \u00E0 l\u2019\u00E9tranger.",
"is_lucrative": true,
"short_summary": "Recherche, d\u00E9veloppement, production, distribution et commercialisation de compos\u00E9s chimiques, radiochimiques, m\u00E9dicaments, produits biotechnologiques, dispositifs m\u00E9dicaux et formulations gal\u00E9niques pour la sant\u00E9 v\u00E9t\u00E9rinaire et humaine."
},
"governance": {
"organ_kind": "raad_van_bestuur",
"n_directors_max": null,
"n_directors_min": 2,
"representation_clause": "deux administrateurs agissant conjointement",
"co_signature_threshold_eur": null
},
"fiscal_year": {
"end_mm_dd": "12-31",
"start_mm_dd": "01-01",
"first_exercise_end_date": "2018-12-31",
"is_prolonged_first_exercise": false
},
"agm_schedule": {
"time": "17:00",
"month": 6,
"rule_text": "premier jeudi de juin \u00E0 dix-sept heures"
},
"founding_event": {
"n_shares_total": 62500,
"n_share_classes": 1,
"bank_attestation": {
"date": "2017-11-21",
"bank_name": "ING",
"amount_eur": 62500.0,
"iban_masked": "BE43 3632 6778 4001"
},
"amount_paid_in_eur": 62500.0,
"incorporation_date": "2017-11-21",
"amount_subscribed_eur": 62500.0,
"art_5_8_no_payment_due": false,
"pre_incorporation_activity_from_date": "2017-10-01"
},
"subject_company": {
"kbo": "0684.906.013",
"email": null,
"region": "waals_gewest",
"website": null,
"name_full": "BoneVet",
"legal_form": "SA",
"name_abbreviated": "BoneVet",
"zetel_address_raw": "6041 Charleroi, Rue Auguste Piccard 48",
"equity_account_type": "available",
"_kbo_extracted_mismatch": "0547.864.809"
},
"initial_directors": [
{
"kind": "rechtspersoon",
"person": null,
"via_org": {
"kbo": "0883.830.544",
"name": "ENRICO BASTIANELLI",
"legal_form": "BV"
},
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2023
},
"rep_person_name": "Enrico BASTIANELLI",
"additional_roles": [
"pr\u00E9sident"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": {
"date": "2017-11-21",
"numac_or_number": "0684906013"
}
},
{
"kind": "natural_person",
"person": {
"name": "Julie Marie-Jos\u00E9 WINAND",
"address": "1400 Nivelles, Avenue de la Libert\u00E9 29, 3F"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2023
},
"rep_person_name": null,
"additional_roles": [],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
}
],
"co_filed_documents": [
"expedition",
"statuten",
"volmacht"
],
"post_incorporation_mandates": [
{
"kind": "volmacht_kbo",
"holder_org_kbo": "0479.092.007",
"holder_org_name": "KREANOVE",
"with_substitution": true,
"holder_person_name": null
}
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | EGEIRO PHARMA |